This article was originally published in The Rose Sheet
Consumer business sales grew 5.2 % at current exchange rates, or 4% adjusted for currency effects, to $4.87 bil. (€1=$1.21) in fiscal 2005, German company notes in Jan. 10 preliminary earnings release. "Except for North America, all regions contributed positive growth rates," firm adds. Consumer EBIT was $560.8 mil. during the year, up 11%. Net sales at current exchange rates rose 5.1% in fiscal 2005 to $5.76 bil., or 3.9% adjusted for currency effects. Earnings before interest and taxes were up 11% to $633.2 mil., while profit after tax was approximately $398 mil. Beiersdorf will release final results March 2...
You may also be interested in...
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.